Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | December 05, 2019 | December 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,360 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 272 · Balance 78,360 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 83 |
Reported balance
Holding disclosure · report date 2026-07-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 83 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
MYRIAD GENETICS INC
Report date December 05, 2019 · Filed December 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,040 |
Reported balance
After 2019-12-05 transaction · row 1
1 source rowRow 1 · 2019-12-05 · Grant · Acquired 11,687 · Balance 76,040 F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 2,050 |
Reported balance
Holding disclosure · report date 2019-12-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,050 |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 7,259 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · derivative · entry 10 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,259 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 7,250 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · derivative · entry 9 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,259 Underlying: Common Stock · 7,250 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 7,250 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · derivative · entry 8 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,509 Underlying: Common Stock · 7,250 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,259 | $54.94 | $398,816.72 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · nonDerivative · entry 6 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,049 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,259 | $4.02 | $29,181.18 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · nonDerivative · entry 5 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,250 | $54.95 | $398,402.00 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · nonDerivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,049 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,250 | $4.02 | $29,145.00 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,250 | $54.94 | $398,329.50 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,049 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| September 12, 2022 Filed Sep 12, 2022 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,250 | $4.02 | $29,145.00 |
DisclosureSEC source: 0001127602-22-022299 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022. Read SEC document |
| July 01, 2022 Filed Jul 12, 2022 20:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 487 | $41.00 | $19,967.00 |
DisclosureSEC source: 0001127602-22-019232 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,049 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $41.00, representing the closing stock price of the Issuer's common stock on July 1, 2022. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001061983-22-000118 · edgardoc.xml · derivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-10 F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2022 and the last such installment vesting on 05/10/2023. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000118 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,562 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2023. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 488 | $38.38 | $18,729.44 |
DisclosureSEC source: 0001061983-22-000087 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,562 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $38.38, representing the Issuer's closing stock price on April 1, 2022. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 00:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,166 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001061983-22-000041 · edgardoc.xml · derivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2022-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 00:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,166 | $5.46 | $22,746.36 |
DisclosureSEC source: 0001061983-22-000041 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 244 | $46.00 | $11,224.00 |
DisclosureSEC source: 0001061983-22-000010 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,499 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $46.00, representing the Issuer's closing stock price on January 3, 2022. F2 · balance_after: Amount includes 2,009 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 22:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,503 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001061983-21-000251 · edgardoc.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,503 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 22:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 8,503 | $40.00 | $340,120.00 |
DisclosureSEC source: 0001061983-21-000251 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,255 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 22:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 8,503 | $5.88 | $49,997.64 |
DisclosureSEC source: 0001061983-21-000251 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 23:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 306 | $36.74 | $11,242.44 |
DisclosureSEC source: 0001061983-21-000229 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,255 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $36.74, representing the Issuer's closing stock price on October 1, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 63 | $19.77 | $1,245.51 |
DisclosureSEC source: 0001061983-21-000188 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,949 F3 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.77, representing the Issuer's closing stock price on July 7, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 01, 2021 Filed Jul 8, 2021 21:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 476 | $20.98 | $9,986.48 |
DisclosureSEC source: 0001061983-21-000188 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,886 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $20.98, representing the Issuer's closing stock price on July 1, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001061983-21-000141 · edgardoc.xml · derivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-12 F3 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-21-000141 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,410 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022. F2 · balance_after: Amount includes 920 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $8.64 | $0.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · derivative · entry 10 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $8.64 | $0.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · derivative · entry 9 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,133 | $0.00 Strike: $8.64 | $0.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · derivative · entry 8 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 1,133 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,100 | $23.31 | $25,641.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · nonDerivative · entry 6 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,410 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,100 | $8.64 | $9,504.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · nonDerivative · entry 5 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,100 | $23.31 | $25,641.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · nonDerivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,410 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,100 | $8.64 | $9,504.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,133 | $24.00 | $27,192.00 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,410 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,133 | $8.64 | $9,789.12 |
DisclosureSEC source: 0001061983-21-000102 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 2, 2021 F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Feb 9, 2022 00:14 UTC Amendment | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 409 | $24.44 | $9,995.96 |
DisclosureSEC source: 0001209191-22-007845 · doc4a.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,819 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all of part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at a per share price of $24.44, representing Issuer's closing stock price on April 1, 2021. F2 · balance_after: Amount includes 920 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 511 | $19.56 | $9,995.16 |
DisclosureSEC source: 0001061983-21-000014 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,410 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021. F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 858 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001061983-20-000193 · edgardoc.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 858 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 858 | $20.31 | $17,425.98 |
DisclosureSEC source: 0001061983-20-000193 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 858 | $12.96 | $11,119.68 |
DisclosureSEC source: 0001061983-20-000193 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 01:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001061983-20-000163 · edgardoc.xml · derivative · entry 7 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 858 Underlying: Common Stock · 1,500 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 01:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001061983-20-000163 · edgardoc.xml · derivative · entry 6 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358 Underlying: Common Stock · 1,500 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 01:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $28.00 | $42,000.00 |
DisclosureSEC source: 0001061983-20-000163 · edgardoc.xml · nonDerivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 01:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,500 | $12.96 | $19,440.00 |
DisclosureSEC source: 0001061983-20-000163 · edgardoc.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 01:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $30.00 | $45,000.00 |
DisclosureSEC source: 0001061983-20-000163 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 01:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,500 | $12.96 | $19,440.00 |
DisclosureSEC source: 0001061983-20-000163 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,333 | $20.93 Strike: $16.86 | $69,759.69 |
DisclosureSEC source: 0001061983-20-000098 · edgardoc.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2020-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,684 | $20.93 | $56,176.12 |
DisclosureSEC source: 0001061983-20-000098 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899 F1 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 649 shares of Common Stock on the net exercise of a stock option to purchase 3,333 shares of Common Stock. The Issuer withheld 2,684 shares of Common Stock underlying the stock option for payment of the exercise price using a stock price on May 19, 2020 of $20.93. In addition to the withholding of 2,684 shares of Common Stock, the Reporting Person has paid $18.26 in cash to the Issuer for the remainder of his exercise price liability. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,333 | $16.86 | $56,194.38 |
DisclosureSEC source: 0001061983-20-000098 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed Apr 8, 2021 22:13 UTC Amendment | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,684 | $20.93 | $56,176.12 |
DisclosureSEC source: 0001061983-21-000107 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,899 F2 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 649 shares of Common Stock on the net exercise of a stock option to purchase 3,333 shares of Common Stock. The Issuer withheld 2,684 shares of Common Stock underlying the stock option for payment of the exercise price using a stock price on May 19, 2020 of $20.93. In addition to the withholding of 2,684 shares of Common Stock, the Reporting Person has paid $18.26 in cash to the Issuer for the remainder of his exercise price liability. F1 · balance_after: This Form 4/A is being filed to report the correct amount of securities beneficially owned following reported transaction(s) on 5/19/2020. The original Form 4 filed on May 20, 2020 by the Reporting Person did not include the 6,000 shares that Reporting Person acquired on November 19, 2019, as reported on Reporting Persons Form 4 filed on 1/02/2020. Read SEC document |
| May 19, 2020 Filed Apr 8, 2021 22:13 UTC Amendment | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,333 | $16.86 | $56,194.38 |
DisclosureSEC source: 0001061983-21-000107 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4/A is being filed to report the correct amount of securities beneficially owned following reported transaction(s) on 5/19/2020. The original Form 4 filed on May 20, 2020 by the Reporting Person did not include the 6,000 shares that Reporting Person acquired on November 19, 2019, as reported on Reporting Persons Form 4 filed on 1/02/2020. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000089 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.